Elanco Animal Health (ELAN)
(Delayed Data from NYSE)
$13.04 USD
-0.27 (-2.03%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $13.04 0.00 (0.00%) 6:34 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
Elanco Animal Health Incorporated (ELAN) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$17.50 | $20.00 | $14.00 | 31.48% |
Price Target
Based on short-term price targets offered by 10 analysts, the average price target for Elanco Animal Health Incorporated comes to $17.50. The forecasts range from a low of $14.00 to a high of $20.00. The average price target represents an increase of 31.48% from the last closing price of $13.31.
Analyst Price Targets (10)
Broker Rating
Elanco Animal Health Incorporated currently has an average brokerage recommendation (ABR) of 1.95 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 11 brokerage firms. The current ABR compares to an ABR of 1.95 a month ago based on 11 recommendations.
Of the 11 recommendations deriving the current ABR, six are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 54.55% and 9.09% of all recommendations. A month ago, Strong Buy made up 54.55%, while Buy represented 9.09%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 6 | 6 | 6 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 1.95 | 1.95 | 1.95 | 1.95 | 1.95 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/12/2024 | Piper Sandler | David M Westenberg | Hold | Hold |
12/7/2023 | Exane BNP Paribas | Research Department | Not Available | Strong Buy |
11/7/2023 | William Blair | Brandon Vazquez | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.95 |
ABR (Last week) | 1.95 |
# of Recs in ABR | 11 |
Average Target Price | $17.50 |
LT Growth Rate | 10.50% |
Industry | Medical - Outpatient and Home Healthcare |
Industry Rank by ABR | 154 of 252 |
Current Quarter EPS Est: | 0.26 |